Gastric Balloon Systems Market Global Report 2026

The gastric balloon systems market size has grown rapidly in recent years. It will grow from $14.55 billion in 2025 to $16.18 billion in 2026 at a compound annual growth rate (CAGR) of 11.2%. The growth in the historic period can be attributed to increasing prevalence of obesity and obesity-related health conditions, rising awareness about non-surgical weight management options, growing demand for minimally invasive bariatric procedures, increasing adoption of endoscopic weight loss interventions, rising healthcare focus on obesity prevention and metabolic health improvement.

The gastric balloon systems market size is expected to see rapid growth in the next few years. It will grow to $24.93 billion in 2030 at a compound annual growth rate (CAGR) of 11.4%. The growth in the forecast period can be attributed to increasing adoption of swallowable gastric balloon capsules, growing demand for personalized obesity treatment approaches, rising expansion of bariatric specialty clinics, increasing development of advanced balloon materials and designs, growing acceptance of temporary weight loss devices among overweight patients. Major trends in the forecast period include increasing adoption of minimally invasive gastric balloon procedures for obesity management, growing preference for swallowable gastric balloon systems to reduce procedural complexity, rising demand for temporary and reversible weight loss interventions, increasing development of adjustable gastric balloon technologies for personalized weight management, growing focus on improving patient comfort and reducing complications associated with gastric balloons.

The increasing prevalence of obesity is anticipated to drive the growth of the gastric balloon systems market in the coming years. Obesity is a chronic health condition defined by excessive accumulation of body fat, which elevates the risk of metabolic disorders, cardiovascular diseases, and other severe health complications. The occurrence of obesity is rising due to sedentary lifestyles, consumption of high-calorie diets, rapid urbanization, and insufficient physical activity, affecting populations in both developed and developing regions. Gastric balloon systems aid in obesity management by offering a temporary, minimally invasive weight-loss approach that promotes early satiety, helps decrease calorie consumption, and enables patients to achieve weight reduction before or as an alternative to bariatric surgery. For example, in May 2025, according to Gov.UK, a UK-based government agency, during 2023 to 2024, approximately 64.5% of adults aged 18 years and above in England were overweight or living with obesity, compared with 64.0% during 2022 to 2023. Hence, the growing prevalence of obesity is contributing to the expansion of the gastric balloon systems market.

Key companies operating in the gastric balloon systems market are focusing on obtaining regulatory approvals for innovative, minimally invasive, procedure-free gastric balloon technologies to expand treatment accessibility and strengthen their market presence. A procedure-free gastric balloon technology is a non-surgical weight loss device that is swallowed as a capsule and placed in the stomach without the need for endoscopy, anesthesia, or surgery, where it occupies space to promote early satiety and reduce food intake for temporary obesity management. For example, in February 2026, Allurion Technologies, a US-based medical device company, received U.S. FDA approval for its Allurion Gastric Balloon System, including the swallowable Allurion Smart Capsule, for short-term weight loss in adults with obesity. The approval enables a procedure-free treatment that does not require surgery, endoscopy, or anesthesia, expanding access to minimally invasive obesity management.

In April 2023, Boston Scientific Corporation, a US-based medical device company specializing in interventional cardiology and peripheral intervention solutions, completed the acquisition of Apollo Endosurgery Inc. for $636 million. Through this acquisition, Boston Scientific intends to enhance its endoscopy portfolio by expanding its minimally invasive gastrointestinal and endobariatric treatment offerings, improving its capabilities in obesity management, accelerating the development of advanced endoluminal procedures, and increasing its global market reach. Apollo Endosurgery Inc. is a US-based medical technology manufacturer focused on producing gastric balloon systems.

Major companies operating in the gastric balloon systems market report are Allurion Technologies Inc., Beijing ZKSK Technology Co. Ltd., Boston Scientific Corporation, CSC MEDSIL, Districlass Médical SA., Endalis, Hélioscopie S.A.S., LEXEL S.R.L., Medicone, ReShape Lifesciences Inc., Silimed Indústria de Implantes Ltda., Spatz FGIA Inc., Suzhou Shenyun Medical Equipment Co. Ltd.

North America was the dominant region in the gastric balloon systems market in 2025. Middle East is expected to be the rapidly growing region in the forecast period. The regions covered in the gastric balloon systems market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the gastric balloon systems market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 3-5 business days.